Drug Development
Rapport Therapeutics raises $150M in funding to advance neuromedicine platform
A clinical-stage biotechnology company announced that it has raised $150 million in funding to advance its neuromedicine platform.
Telemedicine represents ‘next significant change’ in rheumatology clinical trials
Optimal trial participation is an key goal not only for researchers and pharmaceutical companies, but drug development as a whole, but travel requirements can often exclude certain patients with rheumatic diseases before they even begin.
Patient advocacy groups ‘critical’ in rheumatology drug development, advancing transparency
The world of drug development and commercialization relies heavily on industry stakeholders, as well as the investigators and researchers who carry out the trials and evaluate experimental therapies.
New Leukemia & Lymphoma Society president to focus on drug development, health disparities
In his new role as president and CEO of The Leukemia & Lymphoma Society, pediatric hematologist oncologist E. Anders Kolb, MD, aims to expand his life’s work in advancing blood cancer research and therapies for patients of all ages.
Novartis to expand renal pipeline with agreement to acquire Chinook Therapeutics
Novartis announced that the company has agreed to acquire Chinook Therapeutics to expand its renal pipeline, according to a company press release.
‘Pathogenic insights’ may help stratify Sjögren’s patients and inform treatment decisions
DESTIN, Fla. — Stratifying Sjögren’s disease patients by symptoms or biologic parameters may help rheumatologists hit therapeutic targets, according to a presenter at the 2023 Congress of Clinical Rheumatology-East.
Lupus Research Alliance, FDA partner to counter challenges in lupus drug development
The Lupus Research Alliance and the FDA have announced a public-private partnership to increase collaboration and further the advancement of personalized therapies for lupus.
Alto Neuroscience announces $60M in funding for four phase 2 studies
Alto Neuroscience Inc. announced that Alpha Wave Ventures has made a $25 million equity investment to its Series B funding, bringing the total to roughly $60 million as Alto seeks to expand its roster of mental-health related therapeutics.
VIDEO: Drug developer targets neurotransmission to improve symptoms in AD
SAN DIEGO – AmyriAD Therapeutics is focusing on the upregulation of neurotransmission to improve cognition and global function in patients with Alzheimer’s disease, according to CEO Sharon L. Rogers, PhD.